Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Bioscience Ventures gets £2m capital injection

This article was originally published in Clinica

  • News

Executive Summary

Bioscience Ventures, a joint venture between the UK's University of Birmingham and specialty diagnostics company Abingdon Health, has received £2m ($3m) in new capital from its co-owners. The JV, established in November 2010 to develop and commercialise immunodiagnostic products from Birmingham Uni's IP (www.clinica.co.uk, 8 November 2010), will use the funds to accelerate development of its two portfolio companies: SeraScience, which is developing point-of-care tests for diagnosing myeloma; and AltaBioscience, which offers specialty chemical synthesis and analysis services. Edgbaston-based BioScience Ventures itself is also developing a proprietary urine test for diagnosing adrenal cancer. The funds will also go towards further investment in new opportunities within the university's IP.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

It’s Official: FDA Drops Final Rule On LDTs

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

See All
UsernamePublicRestriction

Register

MT099103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By